Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

A Humanized Anti-Interferon-? Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn`s Disease

Study:

A Phase II, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of a Humanized Anti-Interferon-? Monoclonal Antibody (HuZAF) Administered to Patients With Moderate to Severe Crohn`s Disease

Rationale:

n/a

Purpose:

The purpose of the HARMONY study is to assess the safety and efficacy of an investigational drug called HuZAF, in patients with moderate to severe Crohn`s disease (CD). HuZAF is a humanized anti-Interferon-gamma (anti-IFN-?) monoclonal antibody, which binds and blocks IFN-?, a protein in the immune system that is involved in inflammation. Antibodies are proteins normally produced by our immune system to help fight off foreign substances. Scientists have been able to make therapeutic humanized monoclonal antibodies, similar to the antibodies in our bodies, to target diseases.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Crohn`s Disease
Colitis
Intestinal Disease
Gastrointestinal Disease
Digestive System Disease
Drug: anti-Interferon-gamma monoclonal antibody Phase 2

Verified by Facet Biotech March, 2012

Sponsored by: Facet Biotech
Information provided by: Facet Biotech
ClinicalTrials.gov identifier: NCT00072943

Study Type: Interventional

Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

The Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States

n/a

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site